Enliven Therapeutics (ELVN) Insider Trading & Ownership $22.71 -0.44 (-1.90%) (As of 05:22 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Enliven Therapeutics (NASDAQ:ELVN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage29.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)9Amount OfInsider Selling(Last 12 Months)$44.53 M Get ELVN Insider Trade Alerts Want to know when executives and insiders are buying or selling Enliven Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ELVN Insider Buying and Selling by Quarter Ad Brownstone ResearchMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement. Enliven Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/27/2024Benjamin HohlCFOSell5,250$24.89$130,672.50 10/28/2024Benjamin HohlCFOSell6,250$28.56$178,500.00 10/18/2024Anish PatelCOOSell716$30.00$21,480.00 10/18/2024Benjamin HohlCFOSell814$30.00$24,420.00 10/18/2024Joseph P LyssikatosInsiderSell847$30.00$25,410.00 10/18/2024Richard A HeymanDirectorSell817$30.00$24,510.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 10/18/2024Samuel KintzCEOSell924$30.00$27,720.00 10/15/2024Richard A HeymanDirectorSell1,270$27.67$35,140.90 10/9/2024Joseph P LyssikatosInsiderSell37,878$28.16$1,066,644.48 10/9/2024Samuel KintzCEOSell16,710$28.15$470,386.50 10/8/2024Rahul D BallalDirectorSell10,420$28.17$293,531.40 10/7/2024Benjamin HohlCFOSell1,270$27.51$34,937.70 10/7/2024Joseph P LyssikatosInsiderSell2,707$27.61$74,740.27 10/7/2024Samuel KintzCEOSell2,730$27.50$75,075.00 10/4/2024Benjamin HohlCFOSell10,218$27.51$281,097.18 10/4/2024Joseph P LyssikatosInsiderSell7,522$27.51$206,930.22 10/4/2024Richard A HeymanDirectorSell2,825$27.51$77,715.75 10/4/2024Samuel KintzCEOSell12,206$27.51$335,787.06 10/1/2024Joseph P LyssikatosInsiderSell527$27.54$14,513.58 10/1/2024Richard A HeymanDirectorSell518$27.54$14,265.72 10/1/2024Samuel KintzCEOSell526$27.54$14,486.04 9/30/2024Benjamin HohlCFOSell2,000$25.33$50,660.00 9/27/2024Benjamin HohlCFOSell4,250$24.27$103,147.50 8/29/2024Joseph P LyssikatosInsiderSell12,000$22.49$269,880.00 8/27/2024Benjamin HohlCFOSell4,250$22.54$95,795.00 8/26/2024Samuel KintzCEOSell12,000$22.89$274,680.00 8/15/2024Richard A HeymanDirectorSell1,270$23.25$29,527.50 7/31/2024Benjamin HohlCFOSell991$27.53$27,282.23 7/31/2024Joseph P LyssikatosInsiderSell3,099$27.56$85,408.44 7/31/2024Richard A HeymanDirectorSell1,702$27.51$46,822.02 7/31/2024Samuel KintzCEOSell2,270$27.56$62,561.20 7/29/2024Benjamin HohlCFOSell5,250$26.68$140,070.00 7/29/2024Joseph P LyssikatosInsiderSell12,000$26.70$320,400.00 7/25/2024Samuel KintzCEOSell12,000$24.92$299,040.00 7/15/2024Anish PatelCOOSell30,978$25.05$775,998.90 7/15/2024Richard A HeymanDirectorSell1,270$24.80$31,496.00 7/12/2024Anish PatelCOOSell17,475$25.07$438,098.25 7/12/2024Benjamin HohlCFOSell3,000$25.07$75,210.00 6/27/2024Benjamin HohlCFOSell4,250$22.57$95,922.50 6/25/2024Samuel KintzCEOSell12,000$21.66$259,920.00 Man Who Called Nvidia Says: “Your Retirement Is Inside This Building.” (Ad)In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $3 trillion company... And the stock is up massively since Jeff's recommendation. Now, Jeff has found five under-the-radar stocks which could power your retirement.6/6/2024Anish PatelCOOSell1,133$20.06$22,727.98 5/28/2024Benjamin HohlCFOSell4,250$23.18$98,515.00 5/28/2024Samuel KintzCEOSell12,000$23.18$278,160.00 5/16/2024Rishi GuptaDirectorSell1,033,300$22.14$22,877,262.00 5/14/2024Anish PatelCOOSell1,107$25.00$27,675.00 5/9/2024Anish PatelCOOSell260$25.06$6,515.60 5/6/2024Anish PatelCOOSell4,875$22.72$110,760.00 5/3/2024Benjamin HohlCFOSell1,000$22.50$22,500.00 4/29/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 4/29/2024Joseph P. LyssikatosinsiderSell12,000$17.92$215,040.00 4/25/2024Samuel KintzCEOSell12,000$16.89$202,680.00 4/15/2024Richard A HeymanDirectorSell1,270$19.99$25,387.30 4/11/2024Anish PatelCOOSell17,500$25.03$438,025.00 4/11/2024Benjamin HohlCFOSell14,000$24.72$346,080.00 4/11/2024Joseph P. LyssikatosinsiderSell30,000$25.04$751,200.00 4/11/2024Rahul D BallalDirectorSell53,400$23.95$1,278,930.00 4/11/2024Samuel KintzCEOSell47,709$25.04$1,194,633.36 4/8/2024Anish PatelCOOSell4,875$18.60$90,675.00 4/4/2024Rahul D BallalDirectorSell3,485$19.15$66,737.75 4/1/2024Joseph P. LyssikatosinsiderSell12,000$18.60$223,200.00 4/1/2024Rahul D BallalDirectorSell3,237$19.08$61,761.96 3/27/2024Benjamin HohlCFOSell3,250$18.25$59,312.50 3/25/2024Samuel KintzCEOSell12,000$17.56$210,720.00 3/19/2024Richard A HeymanDirectorSell1,270$14.50$18,415.00 3/6/2024Anish PatelCOOSell4,875$15.64$76,245.00 2/29/2024Joseph P. LyssikatosinsiderSell12,000$16.42$197,040.00 2/27/2024Benjamin HohlCFOSell3,250$16.97$55,152.50 2/15/2024Richard A HeymanDirectorSell1,270$17.42$22,123.40 2/6/2024Anish PatelCOOSell4,875$15.11$73,661.25 1/31/20245Am Partners Vi, LlcMajor ShareholderSell500,000$15.00$7,500,000.00 1/30/2024Richard A HeymanDirectorSell1,270$16.41$20,840.70 1/29/2024Benjamin HohlCFOSell3,250$15.81$51,382.50 1/29/2024Joseph P. LyssikatosinsiderSell12,000$15.85$190,200.00 1/25/2024Samuel KintzCEOSell12,000$15.69$188,280.00 1/22/2024Anish PatelCOOSell4,875$15.13$73,758.75 1/2/2024Anish PatelCOOSell11,000$15.00$165,000.00 1/2/2024Benjamin HohlCFOSell9,383$15.01$140,838.83 12/26/2023Anish PatelCOOSell102$15.01$1,531.02 12/26/2023Benjamin HohlCFOSell100$15.00$1,500.00 12/26/2023Samuel KintzCEOSell12,000$14.64$175,680.00 (Data available from 1/1/2013 forward) ELVN Insider Trading Activity - Frequently Asked Questions Who is on Enliven Therapeutics's Insider Roster? The list of insiders at Enliven Therapeutics includes 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta, and Samuel Kintz. Learn more on insiders at ELVN. What percentage of Enliven Therapeutics stock is owned by insiders? 29.20% of Enliven Therapeutics stock is owned by insiders. Learn more on ELVN's insider holdings. Which Enliven Therapeutics insiders have been selling company stock? The following insiders have sold ELVN shares in the last 24 months: 5Am Partners Vi, Llc ($17,502,500.00), Anish Patel ($2,336,926.24), Benjamin Hohl ($2,083,670.54), Joseph P Lyssikatos ($2,063,926.99), Rahul D Ballal ($1,700,961.11), Richard A Heyman ($349,650.29), Rishi Gupta ($22,877,262.00), and Samuel Kintz ($4,548,397.78). How much insider selling is happening at Enliven Therapeutics? Insiders have sold a total of 2,842,942 Enliven Therapeutics shares in the last 24 months for a total of $55,318,056.63 sold. Enliven Therapeutics Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Compensation: $866.41kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder & Chief Scientific Officer Compensation: $632.67kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Compensation: $686.19kMr. Anish Patel Pharm.D. (Age 43)Co-Founder & COO Mr. Benjamin Hohl (Age 34)CFO & Head of Corporate Development Compensation: $488.5k12 recent tradesDr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development More Insider Trading Tools from MarketBeat Related Companies Axsome Therapeutics Insider Buying Apellis Pharmaceuticals Insider Buying Ultragenyx Pharmaceutical Insider Buying Prestige Consumer Healthcare Insider Buying Organon & Co. Insider Buying Avidity Biosciences Insider Buying Biohaven Insider Buying Verona Pharma Insider Buying PTC Therapeutics Insider Buying Perrigo Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:ELVN) was last updated on 12/26/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Coin for November 2024Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this ...Crypto 101 Media | Sponsored“AI Killer” 10x More Powerful Than ChatGPTElon Musk may be about to “kill” the world’s most powerful AI. Very few people are talking about the one AI...Paradigm Press | SponsoredIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
